Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

1.

Loss of Tuberous Sclerosis Complex 2 (TSC2) is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy DA, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A.

Mol Cancer Ther. 2015 Feb 27. pii: molcanther.0768.2014. [Epub ahead of print]

PMID:
25724664
[PubMed - as supplied by publisher]
2.

Safety and Efficacy of 70-150 μm and 100-300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.

Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S.

J Vasc Interv Radiol. 2015 Feb 18. pii: S1051-0443(14)01218-4. doi: 10.1016/j.jvir.2014.12.020. [Epub ahead of print]

PMID:
25704226
[PubMed - as supplied by publisher]
3.

Self-catalysed aerobic oxidization of organic linker in porous crystal for on-demand regulation of sorption behaviours.

Liao PQ, Zhu AX, Zhang WX, Zhang JP, Chen XM.

Nat Commun. 2015 Feb 23;6:6350. doi: 10.1038/ncomms7350.

PMID:
25702689
[PubMed - in process]
4.

Microsatellite instability in gallbladder carcinoma.

Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V.

Virchows Arch. 2015 Feb 14. [Epub ahead of print]

PMID:
25680569
[PubMed - as supplied by publisher]
5.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Jan 21. doi: 10.1038/nature14149. [Epub ahead of print] No abstract available.

PMID:
25607362
[PubMed - as supplied by publisher]
6.

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Castillo CF.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

PMID:
25599322
[PubMed - in process]
7.

Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2015 Jan 10. [Epub ahead of print] No abstract available.

PMID:
25575648
[PubMed - as supplied by publisher]
8.

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

PMID:
25547503
[PubMed - in process]
9.

CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.

Hepatology. 2014 Dec 20. doi: 10.1002/hep.27665. [Epub ahead of print]

PMID:
25529917
[PubMed - as supplied by publisher]
10.

The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2014 Dec 18. [Epub ahead of print]

PMID:
25519926
[PubMed - as supplied by publisher]
11.

Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?

Hesketh RL, Zhu AX, Oklu R.

Diagn Interv Radiol. 2015 Jan-Feb;21(1):78-84. doi: 10.5152/dir.2014.14237.

PMID:
25430530
[PubMed - in process]
Free Article
12.

Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?

Deipolyi AR, Zhu AX, Oklu R.

Am J Clin Oncol. 2014 Oct 20. [Epub ahead of print]

PMID:
25333732
[PubMed - as supplied by publisher]
13.

Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions.

Sheth RA, Arellano RS, Uppot RN, Samir AE, Goyal L, Zhu AX, Gervais DA, Mahmood U.

Radiology. 2015 Mar;274(3):917-26. doi: 10.1148/radiol.14141308. Epub 2014 Oct 10.

PMID:
25302707
[PubMed - in process]
14.

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.

Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX.

Invest New Drugs. 2015 Feb;33(1):128-37. doi: 10.1007/s10637-014-0164-8. Epub 2014 Sep 24.

PMID:
25248753
[PubMed - in process]
15.

Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?

Hesketh RL, Zhu AX, Oklu R.

Am J Clin Oncol. 2014 Sep 18. [Epub ahead of print]

PMID:
25238287
[PubMed - as supplied by publisher]
16.

A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors.

Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX.

Pract Radiat Oncol. 2014 Sep-Oct;4(5):316-22. doi: 10.1016/j.prro.2013.10.002. Epub 2013 Nov 22.

PMID:
25194100
[PubMed - in process]
17.

Hepatobiliary cancers, version 2.2014.

Benson AB 3rd, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H.

J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82.

PMID:
25099447
[PubMed - in process]
18.

High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival.

Deipolyi AR, Iafrate AJ, Zhu AX, Ergul EA, Ganguli S, Oklu R.

J Vasc Interv Radiol. 2014 Oct;25(10):1604-8. doi: 10.1016/j.jvir.2014.06.019. Epub 2014 Jul 30.

PMID:
25086965
[PubMed - in process]
19.

Putative role of ischemic postconditioning in a rat model of limb ischemia and reperfusion: involvement of hypoxia-inducible factor-1α expression.

Wang T, Zhou YT, Chen XN, Zhu AX.

Braz J Med Biol Res. 2014 Sep;47(9):738-45. Epub 2014 Jul 25.

PMID:
25075575
[PubMed - in process]
Free PMC Article
20.

Remote ischemic postconditioning protects against gastric mucosal lesions in rats.

Wang T, Zhou YT, Chen XN, Zhu AX, Wu BH.

World J Gastroenterol. 2014 Jul 28;20(28):9519-27. doi: 10.3748/wjg.v20.i28.9519.

PMID:
25071347
[PubMed - in process]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk